Pruritus clinical trials at UCSF

2 in progress, 0 open to eligible people

Showing trials for

  • A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

    Sorry, not accepting new patients

    An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.

    San Francisco, California and other locations

  • PRISM Study-Pruritus Relief Through Itch Scratch Modulation

    Sorry, in progress, not accepting new patients

    To investigate the anti-pruritic efficacy and safety of Nalbuphine ER (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.

    San Francisco, California and other locations

Last updated: